13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
87,500 |
29.05.24 15:58:52 |
-1,360 |
-1,53% |
88,130 |
88,290 |
87,800 |
88,860 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
895,000 |
29.05.24 18:20:50 |
-6,200 |
-0,69% |
891,800 |
896,800 |
888,200 |
901,200 |